August 29, 2022, BALDWIN PARK, CA, — Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years. StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
PeptiGrowth Inc. is Launching A Novel Synthetic Peptide BMP4,7 inhibitor (Noggin-like peptide)
July 26, 2022, Tokyo, Japan – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide “BMP4,7 inhibitor (Noggin-like peptide)” which binds to several Bone Morphogenetic Proteins (BMPs) to inhibit its activity like Noggin. It will be marketing this product from July, 2022. [Read more…]
Placental Stem Cells – Interview with Dr. Ornella Parolini of IPLASS
In this interview with Dr. Ornella Parolini, Director of the E. Menni Research Center in Italy, we discussed her pioneering research on human placental stem cells. Her research is focused on the immunomodulatory and anti-inflammatory properties of amniotic and chorionic membrane cells. She is also President of the International Placenta Stem Cell Society (IPLASS), making her a globally recognized expert.
In addition to Dr. Robert Harari who holds a wide range of placental stem cell patents, Dr. Parolini is one of the world’s leading experts on placental stem cells and their therapeutic applications.
In this article:
Stem Cell Thought-Leaders—and What You Can Learn From Them
Without question, some of BioInformant’s most popular content has been our interviews with key opinion leaders (KOL). Highlighted below are five interviews that have been widely shared across the stem cell industry. The first interview with Dr. Sadiq has gotten more than 2,200 shares on social media, so you definitely need to check it out. Enjoy!
Stem Cell Therapy Shows Promise for Treatment of MS – Q&A with Dr. Sadiq of the Tisch MS Research Center of NY
In breaking news from the Tisch MS Research Center of New York, Dr. Sadiq announced he is pursuing a Phase II clinical trial exploring the use of stem cells in the treatment of MS. The announcement followed positive results from a FDA-approved Phase I stem cell trial in which MS patients received multiple spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (called MSC-NPs). Compellingly, it was the first time ever that a treatment method has demonstrated reversal of established disability in MS patients. [Read more…]
I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes
PALO ALTO, Calif., May 11, 2022 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up in the field of GMP cell manufacturing CDMO, announced that the company, in collaboration with Genequest Inc., a Tokyo-based direct-to-consumer genetic testing service provider, established a data-driven method to identify potential cell donors with specific haplotypes. With this high-throughput method, the company has already succeeded in identifying 1,547 HLA-homozygous potential donors and has already generated iPSCs. [Read more…]
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 62
- Next Page »